Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How many JAK inhibitors in myelofibrosis?

Best practice & research. Clinical haematology - 1 Jun 2014

Ferreira Bruna Velosa, Harrison Claire

Abstract excerpt

The discovery of the activating mutation JAK2 V617F ushered a new era in MPN which included new diagnostic and prognostic criteria as well as a potential therapeutic target. JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF). In this article entitled "How...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Benzamides
Share to Bridged-Ring Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Janus Kinase 1

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Source

Identifiers

PMID: 25189729
DOI: 10.1016/j.beha.2014.07.010

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How many JAK inhibitors in myelofibrosis?PMID 25189729Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].Semantic proximity Read ↗

JAK2 inhibitors for myeloproliferative neoplasms: what is next?Semantic proximity Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 inhibitors: are they the solution?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.